Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
about
Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detectionGenomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast CancerCircadian disruption and breast cancer: an epigenetic link?Acetylation of the pro-apoptotic factor, p53 in the hippocampus following cerebral ischemia and modulation by estrogenEpigenetic regulation in estrogen receptor positive breast cancer--role in treatment responseUnraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis.Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasisTumor suppressor genes are frequently methylated in lymph node metastases of breast cancersArray-based DNA methylation profiling for breast cancer subtype discrimination.DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer.Methylation at global LINE-1 repeats in human blood are affected by gender but not by age or natural hormone cycles.DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cellsFrequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.Neighborhood rough set reduction-based gene selection and prioritization for gene expression profile analysis and molecular cancer classification.Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients.Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancerDNA methylation epigenotypes in breast cancer molecular subtypes.Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features.Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumorsDownregulation of 14-3-3σ correlates with multistage carcinogenesis and poor prognosis of esophageal squamous cell carcinomaBody mass and DNA promoter methylation in breast tumors in the Western New York Exposures and Breast Cancer Study.Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis.Epigenetics in breast and prostate cancerAberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancerAssessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumourMethylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease.Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancerEpigenetic silencing of NKD2, a major component of Wnt signaling, promotes breast cancer growth.A common promoter hypomethylation signature in invasive breast, liver and prostate cancer cell lines reveals novel targets involved in cancer invasiveness.DNA methylation and hormone receptor status in breast cancer.DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification.RASSF1A Promoter Methylation Levels Positively Correlate with Estrogen Receptor Expression in Breast Cancer Patients.Inherited and acquired alterations in development of breast cancer.The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patientsDNA promoter hypermethylation in nipple fluid: a potential tool for early breast cancer detectionDNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patientsDNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study
P2860
Q24646396-DFD5A3CA-939B-4B8A-8052-4B45CC301C74Q26738987-C894F650-9BFC-459E-B0E4-8DF27BBD6781Q26798258-70127A40-B74C-40B1-885E-CAFF7056EAB5Q27314528-D7623824-328E-4A6B-AD27-2D6D522017CEQ27694612-79E3A33A-D16E-47ED-BF88-32C2C038108AQ33570282-37E44DE4-5316-40E6-8ACE-E1AE6C51117DQ33582678-A3EC3829-6CDB-4F07-B55A-3D4CD95529B1Q33636156-CF8D9452-6E0A-4194-A15E-45BE3059DA39Q33689442-5637EBCE-BB50-4A60-B993-F1FE108AA7DAQ33816178-61283DC1-F304-4FB4-8850-22118F0D032BQ33817330-202C8C19-2B64-4B8D-9B01-585780529EF9Q33818016-1519A331-D03A-45C3-AD64-EAACA61DE542Q33878937-3DB3BE67-130A-46A0-8623-FFA8C4D847B1Q33892868-7E18FB65-65B5-40EA-AB2C-9B1DDAF7B009Q33960955-AD76066C-AD39-4C02-B045-5A53AA4BE046Q33960985-65D08376-E350-4D36-9171-05276F49B5BBQ33961765-6A10C4DD-31D6-4E3B-9196-13D63900717AQ34303319-6214D195-D108-4963-942C-6ED4FF7C8B2FQ34305047-FF2927D7-E3E5-4C95-A53E-9EA8BE723A60Q34989097-A2412E71-278A-4C00-B8BF-953ED6FA6E8AQ35000210-A40E7FF5-C48F-461C-9CF6-5B0CECFA4A93Q35008011-E53DEE65-723C-475A-A989-5E48DC89D0E8Q35152011-01526A5A-1A38-4592-9085-398C72B45B96Q35163939-E0737090-5A22-4570-AA38-D73F5FCF439FQ35172269-3EAED2E3-56C6-499D-99CE-62F02CED1D8AQ35190483-767088DF-EFAA-452B-B254-3EA7101064A4Q35624942-89F11322-7AC0-433A-B93E-07A250279F17Q35801963-4F396D93-BC13-4F26-BB56-C1BC23145A2CQ35958967-B3E0BFC4-58EF-4FC0-BFB2-7274F6AA5485Q36061986-7F427905-3E4F-4F07-9D34-BD0AC82C7E19Q36355895-373FE199-D52C-4BBE-8AF0-8B6140272ED7Q36545127-69E4FCB3-31B4-4E77-AB4C-D717A7B97235Q36583742-E38DA531-CDD4-45F5-9424-C1CD41C09F04Q36768855-D9A021E5-8B3F-4FAD-97DE-BD673E4107F5Q36865048-13405D56-E5FC-400D-9CE9-A00E41CCD1B1Q36925229-77EDA067-AB20-4DE6-8B37-0BB3FE5BA51DQ37177902-8FC4C66B-BE50-49A4-A550-71F5F8696244Q37269445-B0D3694D-24AE-4F3C-B4C8-01A11B4E321EQ37285274-F6C7A5A4-2418-4321-B86B-54941CF5834CQ37308097-E799FD15-A51B-4DF7-A98A-1D8F7210EC3E
P2860
Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Correlation between CpG methyl ...... ptor status in breast cancers.
@ast
Correlation between CpG methyl ...... ptor status in breast cancers.
@en
type
label
Correlation between CpG methyl ...... ptor status in breast cancers.
@ast
Correlation between CpG methyl ...... ptor status in breast cancers.
@en
prefLabel
Correlation between CpG methyl ...... ptor status in breast cancers.
@ast
Correlation between CpG methyl ...... ptor status in breast cancers.
@en
P2093
P2860
P356
P1476
Correlation between CpG methyl ...... ptor status in breast cancers.
@en
P2093
Aysegul A Sahin
Daniel G Rosen
Jaroslav Jelinek
Jean-Pierre J Issa
Jinsong Liu
Kelly K Hunt
Lanlan Shen
Miao Huang
Robert C Bast
Shaoyi Huan
P2860
P2888
P356
10.1186/BCR1762
P577
2007-01-01T00:00:00Z
P5875
P6179
1012833701